Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus
Sponsor: National Cancer Institute (NCI)
Terminated
Poor accrual
Other terminated trials from National Cancer Institute (NCI)
Listed as NCT01061606, this PHASE2 trial focuses on Recurrent Uterine Sarcoma and Uterine Carcinosarcoma and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .